文献速递中医内科中药与中成药合理使用

植物提取物治疗心力衰竭:随机对照试验的网络Meta分析

Effects of plant extracts on patients with heart failure: a network meta-analysis of randomized controlled trials.
PubMed 文献 · Front Pharmacol · 2025-11-05

本研究通过系统综述与网络Meta分析评估植物提取物对心力衰竭患者的疗效,纳入20项研究共2077例患者。结果显示黄芪提取物在改善6分钟步行试验和降低TNF-α方面最优,参附提取物在降低BNP和改善生活质量方面更优,红参提取物改善LVEF更有效,银杏提取物改善NYHA分级更佳。

要点

  • 黄芪提取物在改善6分钟步行试验和降低TNF-α方面排名最高。
  • 参附提取物在降低BNP和改善生活质量方面表现更优。
  • 红参提取物改善LVEF更有效,银杏提取物改善NYHA分级更佳。

核心结论

  • 黄芪、红参、银杏、Terminalia arjuna和参附提取物在心力衰竭管理中显示出显著疗效,可基于心脏功能指标改善选择最优植物提取物。
  • 仍需高质量大规模随机对照试验验证结果并确定最佳植物提取物使用方案。

研究设计与样本

  • 系统综述与网络Meta分析,检索PubMed、Embase和Cochrane Library数据库。
  • 纳入20项随机对照试验,共2077例心力衰竭患者。

主要发现

  • 黄芪提取物改善6分钟步行试验的SUCRA为90.70%,降低TNF-α的SUCRA为74.4%。
  • 参附提取物降低BNP的SUCRA为68.2%,改善生活质量的SUCRA为77.0%。
  • 红参提取物改善LVEF的SUCRA为77.9%,银杏提取物改善NYHA分级的SUCRA为76.5%。

临床怎么用

  • 可根据患者心脏功能指标(如6分钟步行试验、BNP、LVEF、NYHA分级)选择相应植物提取物。
  • 黄芪提取物可用于改善运动耐量和降低TNF-α,参附提取物可用于降低BNP和改善生活质量。

局限性

  • 纳入研究存在异质性和方法学问题,需进一步高质量大规模随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Heart failure (HF) is a major global health challenge. Traditional therapies have limitations, while recent studies highlight plant extracts' potential due to their medicinal properties and milder side effects. OBJECTIVE: This study conducts a systematic review and network meta-analysis (NMA) to assess the therapeutic effects of plant extracts on patients with heart failure, providing robust evidence for clinical practice. MATERIALS AND METHODS: A comprehensive search of databases, including PubMed, Embase, and Cochrane Library, was performed. Studies were screened using predefined criteria to extract data and assess quality. Network meta-analysis enabled direct/indirect comparisons of multiple plant extracts' efficacy in heart failure intervention. RESULTS: A total of 20 studies encompassing 2,077 patients were incorporated into the analysis. Astragalus extract demonstrated the highest efficacy in enhancing the 6-min walk test (6-MWT) score (surface under the cumulative ranking curve [SUCRA]: 90.70%) and reducing tumor necrosis factor-alpha (TNF-α) levels (SUCRA: 74.4%). Shenfu extract exhibited superior efficacy in decreasing B-type natriuretic peptide (BNP) values (SUCRA: 68.2%) and enhancing the quality of life (QL) (SUCRA: 77.0%). Red ginseng extract was more effective in improving left ventricular ejection fraction (LVEF) (SUCRA: 77.9%), while Ginkgo biloba extract showed greater efficacy in ameliorating New York Heart Association (NYHA) functional classification (SUCRA: 76.5%). Despite these findings, heterogeneity and methodological issues in the studies warrant further high-quality, large-scale randomized controlled trials (RCTs) to validate the results and determine the optimal plant extract use in heart failure treatment. CONCLUSION: Astragalus extract, red ginseng extract, Ginkgo biloba extract, Terminalia arjuna extract, and Shenfu extract have demonstrated significant efficacy in heart failure management in the study for the selection of optimal plant extracts based on enhanced indicators of cardiac function outcomes. Continued research through rigorous randomized controlled trials is essential to substantiate and refine the current evidence.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Deng J, Huang Y, Fu D, et al. Effects of plant extracts on patients with heart failure: a network meta-analysis of randomized controlled trials. Front Pharmacol. 2025. PMID: 41268442. doi:10.3389/fphar.2025.1648811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。